Research statistics
Semaglutide research: publications and trials
At a glance
Publications, all years
4,968
Since 2012
Publications in 2026 so far
1,707
Through November 15, 2026
Human clinical research
40.2%
1,979 of 4,922 classified
Registered clinical trials
658
ClinicalTrials.gov
Randomized controlled trials
372
Publications reporting an RCT in people
Systematic reviews and meta-analyses
446
Preclinical studies
14.3%
450 animal · 88 in vitro · 164 computational
Records that only mention it
642
Not counted above
Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 46 publications are not yet classified by study type.
What to keep in mind
- Some completed trials have neither posted results nor a linked results publication.
Publications by year
Semaglutide publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2012 | 0 | 0 | 1 | 0 | 1 |
| 2013 | 0 | 0 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 | 1 | 3 |
| 2015 | 2 | 1 | 0 | 0 | 3 |
| 2016 | 2 | 0 | 6 | 2 | 10 |
| 2017 | 13 | 1 | 27 | 15 | 56 |
| 2018 | 22 | 9 | 54 | 9 | 94 |
| 2019 | 26 | 13 | 35 | 20 | 94 |
| 2020 | 32 | 19 | 56 | 12 | 119 |
| 2021 | 55 | 27 | 59 | 46 | 187 |
| 2022 | 76 | 50 | 74 | 21 | 221 |
| 2023 | 147 | 63 | 80 | 80 | 370 |
| 2024 | 327 | 113 | 200 | 174 | 814 |
| 2025 | 559 | 172 | 304 | 253 | 1,288 |
| 2026 (to date) | 718 | 233 | 544 | 212 | 1,707 |
Study types
| Observational human study | 1,165 |
|---|---|
| Review | 996 |
| Editorial, letter or other | 783 |
| Animal study | 450 |
| Randomized controlled trial | 372 |
| Case report | 328 |
| Meta-analysis | 255 |
| Systematic review | 191 |
| Computational study | 164 |
| Other clinical trial | 114 |
| In vitro study | 88 |
| Not yet classified | 46 |
| Guideline or consensus | 16 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 3,363 |
|---|---|
| Obesity and weight management | 2,074 |
| Endocrinology | 1,887 |
| Cardiovascular | 948 |
| Gastrointestinal | 581 |
| Neurological and mental health | 518 |
| Immune system | 228 |
| Reproductive and sexual health | 206 |
| Musculoskeletal | 157 |
| Oncology | 106 |
| Cognitive health | 96 |
| Dermatology | 82 |
Registered clinical trials
102 of 281 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.
Completed: 320 · Recruiting: 138 · Not yet recruiting: 79 · Active, not recruiting: 55 · Unknown status: 35 · Enrolling by invitation: 11 · Withdrawn: 11 · Terminated: 8 · Suspended: 1
Early phase 1: 5 · Phase not applicable: 135 · Phase 1: 117 · Phase 1 / Phase 2: 8 · Phase 2: 112 · Phase 2 / Phase 3: 12 · Phase 3: 161 · Phase 4: 108
The 50 most recently started of 658 trials.
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Exploring time-varying cardiovascular effects of GLP-1 receptor agonists: A multi-state network meta-analysis of cardiovascular outcome trials.
Diabetes research and clinical practice · November 6, 2026 · Meta-analysis · cited 0 times
PMID 42994759 · DOI 10.1016/j.diabres.2026.113638 · Reviews and meta-analyses
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
Diabetes, obesity & metabolism · October 27, 2026 · Meta-analysis · cited 0 times
PMID 42935221 · DOI 10.1111/dom.71485 · Reviews and meta-analyses
- Glucagon-like peptide-1 receptor agonists and risk of arrhythmias: A network meta-analysis.
Heart rhythm · October 26, 2026 · Meta-analysis · cited 0 times
PMID 42933519 · DOI 10.1016/j.hrthm.2026.10.052 · Reviews and meta-analyses
- Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis.
European journal of clinical pharmacology · October 24, 2026 · Meta-analysis · cited 0 times
PMID 42920001 · DOI 10.1007/s00228-026-04206-4 · Reviews and meta-analyses
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
Frontiers in endocrinology · October 2, 2026 · Meta-analysis · cited 0 times · open access
PMID 42890523 · DOI 10.3389/fendo.2026.1903335 · Reviews and meta-analyses
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis.
Medicine · October 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42937793 · DOI 10.1097/md.0000000000051306 · Reviews and meta-analyses
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
Clinical obesity · October 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42584177 · DOI 10.1111/cob.70105 · Reviews and meta-analyses
- Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
Clinical obesity · October 1, 2026 · Meta-analysis · cited 0 times · open access
PMID 42670242 · DOI 10.1111/cob.70111 · Reviews and meta-analyses
- Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
International journal of obesity (2005) · September 28, 2026 · Meta-analysis · cited 0 times · open access
PMID 42806056 · DOI 10.1038/s41366-026-02229-6 · Reviews and meta-analyses
- GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.
Drugs · September 26, 2026 · Meta-analysis · cited 0 times
PMID 42791433 · DOI 10.1007/s40265-026-02380-4 · Reviews and meta-analyses
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine · September 15, 2016 · Randomized controlled trial · cited 6,867 times · open access
PMID 27633186 · DOI 10.1056/nejmoa1607141 · Human clinical research
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine · February 10, 2021 · Randomized controlled trial · cited 5,142 times · open access
PMID 33567185 · DOI 10.1056/nejmoa2032183 · Human clinical research
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The New England journal of medicine · November 11, 2023 · Randomized controlled trial · cited 3,168 times · open access
PMID 37952131 · DOI 10.1056/nejmoa2307563 · Human clinical research
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
The New England journal of medicine · June 25, 2021 · Randomized controlled trial · cited 2,072 times · open access
PMID 34170647 · DOI 10.1056/nejmoa2107519 · Human clinical research
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
The New England journal of medicine · November 13, 2020 · Randomized controlled trial · cited 2,024 times · open access
PMID 33185364 · DOI 10.1056/nejmoa2028395 · Human clinical research
Latest publications
- Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review.
BMC oral health · November 14, 2026 · Systematic review · cited 0 times
PMID 43034163 · DOI 10.1186/s12903-026-10305-6 · Reviews and meta-analyses
- Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.
The lancet. Diabetes & endocrinology · November 14, 2026 · Not yet classified · cited 0 times
PMID 43033821 · DOI 10.1016/s2213-8587(26)00275-5 · Not yet classified
- Rare GLP1R variants diminish the weight loss effect of semaglutide but not of tirzepatide.
Nature metabolism · November 13, 2026 · Not yet classified · cited 0 times
PMID 43026316 · DOI 10.1038/s42255-026-01661-2 · Not yet classified
- Weight loss at a cost: Semaglutide and PYY3-36 aggravate pre-existing metabolic osteoporosis in female Wistar rats.
Bone · November 13, 2026 · Animal study · cited 0 times
PMID 43025770 · DOI 10.1016/j.bone.2026.118170 · Animal studies
- Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks.
Minerva endocrinology · November 13, 2026 · Review · cited 0 times
PMID 43021748 · DOI 10.23736/s2724-6507.26.04655-5 · Reviews and meta-analyses
- GLP-1 dose escalation and disputed ignition interlock alcohol results: Case report.
The Medico-legal journal · November 12, 2026 · Case report · cited 0 times · open access
PMID 43018099 · DOI 10.1177/00258172261476035 · Human clinical research
- GLP-1-based Therapies in MASH: From Metabolic Benefits to an Improvement in Liver Fibrosis.
Internal medicine (Tokyo, Japan) · November 12, 2026 · Review · cited 0 times
PMID 43014742 · DOI 10.2169/internalmedicine.8562-26 · Reviews and meta-analyses
- Gut-hormone receptor systems in the eye: Pharmacological, local and putative endocrine signalling.
European journal of ophthalmology · November 11, 2026 · Review · cited 0 times · open access
PMID 43012562 · DOI 10.1177/11206721261507148 · Reviews and meta-analyses
- Follow-up discrepancies in a TriNetX-based comparison of preoperative tirzepatide or semaglutide use and postoperative total hip/knee arthroplasty outcomes.
European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · November 11, 2026 · Editorial, letter or other · cited 0 times
PMID 43012889 · DOI 10.1007/s00590-026-05030-3 · Commentary and other
- Rare GLP1R variants attenuate weight loss with semaglutide but not tirzepatide.
Nature metabolism · November 11, 2026 · Observational human study · cited 0 times
PMID 43015368 · DOI 10.1038/s42255-026-01656-z · Human clinical research
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Kayshild; NN9535; NN9536; NN9924; Ozempic; Rybelsus; Semaglutide; Wegovy
((TITLE_ABS:"Kayshild" OR CHEM:"Kayshild") OR (TITLE_ABS:"NN9535" OR CHEM:"NN9535" OR TITLE_ABS:"NN 9535" OR CHEM:"NN 9535") OR (TITLE_ABS:"NN9536" OR CHEM:"NN9536" OR TITLE_ABS:"NN 9536" OR CHEM:"NN 9536") OR (TITLE_ABS:"NN9924" OR CHEM:"NN9924" OR TITLE_ABS:"NN 9924" OR CHEM:"NN 9924") OR (TITLE_ABS:"Ozempic" OR CHEM:"Ozempic") OR (TITLE_ABS:"Rybelsus" OR CHEM:"Rybelsus") OR (TITLE_ABS:"Semaglutide" OR CHEM:"Semaglutide") OR (TITLE_ABS:"Wegovy" OR CHEM:"Wegovy")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Semaglutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/semaglutide